MSA-2 NEW
| Price | $34 | $48 | $80 |
| Package | 1mg | 2mg | 5mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-05-26 |
Product Details
| Product Name: MSA-2 | CAS No.: 129425-81-6 |
| Purity: 98.88% | Supply Ability: 10g |
| Release date: 2025/05/26 |
Product Introduction
Bioactivity
| Name | MSA-2 |
| Description | MSA-2 is an orally available non-nucleotide STING agonist. The non-covalent dimer of MSA-2 binds to STING with nanomolar affinity. It shows anti-tumor activity in syngeneic mouse tumor models, synergizes with anti-PD-1, stimulates tumor secretion of interferon-β, induces tumor regression, and has long-lasting anti-tumor immunity. [3] |
| Animal Research | Animal Model was MC38 tumor-bearing C57BL6 mice,and The dosage was 60 mg/kg.Administration was P.o.;s.c (50 mg/kg);single dose[1] |
| In vitro | METHODS: PK-15 cells were treated with MSA-2 at concentrations of 20, 30, 40 and 50 μM for 24 hours and then infected with SVV at 10 MOI. SVV RNA levels in treated cells were detected by RT-qPCR at 24 h post-infection (hpi). RESULTS Viral RNA levels in MSA-2-treated cells were significantly reduced in a dose-dependent manner. [2] |
| In vivo | METHODS: The EMT-6 mouse model was treated with MSA-2 (50 mg/kg, orally), and the changes in intratumoral cytokines and chemokines after MSA-2 treatment in vivo were explored. RESULTS IFN-β, IL-6, TNF-α, IFN-γ, and classical activation-associated chemokines including CCL2, CCL3, CCL4, CCL5, CXCL1, CXCL9, and CXCL10 were significantly upregulated in EMT-6 tissues. [1] METHODS: MSA-2 was orally administered at a single dose of 50 mg/kg to mice bearing U14 and TC-1 cervical tumor models. Mice were treated with 5 mg/kg of anti-PD-1 every other day for a total of 3 treatments. Tumor volume was assessed every other day. RESULTS The tumor volume of mice was significantly reduced. [2] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 50 mg/mL (169.88 mM), Sonication and heating to 80℃ are recommended. |
| Keywords | tumor | TNF-α | TMEM173 | STING | Stimulator of Interferon Genes | secretion | MSA-2 | MSA2 | MSA 2 | MPYS | MITA | MC38 | interferon-β | Inhibitor | inhibit | immunity | ERIS |
| Inhibitors Related | 2',3'-cGAMP sodium | SR-717 | H-151 | ChX710 | SN-008 | Vadimezan | Dazostinag disodium | C-176 | Cridanimod | CCCP | diABZI STING agonist-1 trihydrochloride | C-178 |
| Related Compound Libraries | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library | NO PAINS Compound Library | Immuno-Oncology Compound Library | Orally Active Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Covalent Inhibitor Library | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $3.00/1000KG |
VIP1Y
|
ChemFine International Co.,Ltd.
|
2024-07-16 | |
| $0.00/1G |
VIP1Y
|
Shenzhen Nexcon Pharmatechs Ltd.
|
2025-05-30 | |
| $0.00/1kg |
VIP2Y
|
Shandong Hanjiang Chemical Co., Ltd
|
2024-01-12 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY